Clinical Trials Logo
  1. Home
  2. Vernal Keratoconjunctivitis
  3. NCT03557203

Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

Vernal Keratoconjunctivitis Clinical Trial

Official title:
Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Steroid Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

Clinical Trial Summary

To evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis.

Clinical Trial Description

Treatment of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) is a challenge for the ophthalmologist and patients because of its wide variation in presentation and recurrence in nature. Patients has to be dependent on long term steroid control and suffered from complications, such as steroid glaucoma and secondary infection. About 32% of VKC patients is refractory to steroid treatment and another 35.4% of patients showed partial response. Tacrolimus ointment or eye drops are promising anti-inflammatory agents that have been shown very effective against VKC for patients suffering from severe VKC resistant to topical cyclosporine. Although tacrolimus eye drops is very effective in severe cases of VKC, unfortunately, it is only available in limited countries. Because of the unavailability of tacrolimus eye drops and side effect of long-tern steroid use, we tried to find other options for these severe VKC and AKC. Because there will be concomitant atopic dermatitis in the eyelid of severe cases of VKC and AKC, we retrospectively collected in cases using topical tacrolimus dermatological ointment on the skin of upper eye lid in the treatment of severe VKC and AKC with concomitant atopic dermatitis. Here, we reported 10 cases with either VKC or AKC whose symptoms resolved significantly with dermatologic tacrolimus ointment applying on eyelids. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03557203
Study type Observational
Source National Taiwan University Hospital
Contact I-Jong Wang, professor
Phone 886-2-23123456
Email ijong@ntu.edu.tw
Status Recruiting
Phase
Start date June 1, 2018
Completion date May 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT05076084 - Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis
Recruiting NCT02057822 - Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months N/A
Completed NCT03464435 - A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Phase 4
Completed NCT00445120 - Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment Phase 2/Phase 3
Completed NCT01211327 - Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Phase 4
Completed NCT05353101 - Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial Phase 1
Not yet recruiting NCT04705584 - Topical Immuonosuppressant Drugs in Spring Catarrh N/A
Completed NCT03379311 - A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis Phase 1
Completed NCT00426023 - Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis Phase 3
Completed NCT01751126 - Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis Phase 3
Recruiting NCT02456025 - Topical Tacrolimus in Vernal Keratoconjunctivitis Phase 4